Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Biodexa Pharmaceuticals ( (BDRX) ) has issued an announcement.
On June 27, 2025, Biodexa Pharmaceuticals announced that all resolutions proposed at its Annual General Meeting on June 26, 2025, were successfully passed. This development reflects the company’s ongoing commitment to its strategic goals and may influence its future operations and stakeholder confidence.
The most recent analyst rating on (BDRX) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Biodexa Pharmaceuticals stock, see the BDRX Stock Forecast page.
Spark’s Take on BDRX Stock
According to Spark, TipRanks’ AI Analyst, BDRX is a Neutral.
Biodexa Pharmaceuticals has a low overall stock score of 45, driven by significant financial challenges, bearish technical indicators, and a poor valuation. The lack of positive earnings guidance further adds to the uncertainty. The company must improve financial performance and operational efficiency to enhance investor confidence.
To see Spark’s full report on BDRX stock, click here.
More about Biodexa Pharmaceuticals
Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company listed on NASDAQ under the ticker BDRX. The company is focused on developing innovative products to treat diseases with unmet medical needs. Its lead development programs include eRapa for Familial Adenomatous Polyposis and Non Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for aggressive rare/orphan brain cancer indications. Biodexa is supported by proprietary drug delivery technologies and is headquartered in Cardiff, UK.
Average Trading Volume: 2,545,089
Technical Sentiment Signal: Sell
Current Market Cap: $608.4K
For detailed information about BDRX stock, go to TipRanks’ Stock Analysis page.